Amplifon Enters U.S. Hearing Care Market As Bausch & Lomb Bows Out
This article was originally published in The Gray Sheet
Executive Summary
Privately held Italian hearing care firm Amplifon S.p.A. is gaining access to the American market through the acquisition of the Miracle-Ear hearing aid business from Bausch & Lomb. Announced July 12, the deal is expected to close by the end of the summer.
You may also be interested in...
Bausch & Lomb
Sale of B&L's Miracle-Ear hearing aid business to privately held Italian firm Amplifon, S.p.A. is complete, the company announces Aug. 30 (1"The Gray Sheet" July 19, p. 5). Sale of B&L's final non-core business, Charles River Laboratories, to Global Health Care Partners, a unit of investment banking firm Donaldson, Lufkin & Jenrette's private equity fund, DLJ Merchant Banking, is expected to close by the end of September
Bausch & Lomb
Sale of B&L's Miracle-Ear hearing aid business to privately held Italian firm Amplifon, S.p.A. is complete, the company announces Aug. 30 (1"The Gray Sheet" July 19, p. 5). Sale of B&L's final non-core business, Charles River Laboratories, to Global Health Care Partners, a unit of investment banking firm Donaldson, Lufkin & Jenrette's private equity fund, DLJ Merchant Banking, is expected to close by the end of September
B&L Hydroview IOL Approvable Vote Includes Modification To Incision Size
Bausch & Lomb's Hydroview Model H60M intraocular lens (IOL) is approvable for refilling the functionally intact human capsule following cataract removal provided labeling include a recommended mean incision size of 3.9 mm (+/- 2 standard deviations), FDA's Ophthalmic Devices Panel unanimously agreed (12-0) at its July 23 meeting.